Call for Papers

Click here to read the full issue in your browser Follow us

Dear VIJAY PITHADIA: Your December 2013 digital issue of P&T journal is available. This issue contains: Feature articles   Antithrombin III Utilization in a Large Teaching Hospital In a retrospective study to assess the use of antithrombin concentrates, the authors judged the plasma-derived product (Thrombate III) to be more cost-effective than the recombinant human form (ATryn) for patients with hereditary antithrombin deficiency.   Calculating the Dose of Subcutaneous Immunoglobulin For Primary Immunodeficiency Disease in Patients Switched From Intravenous to Subcutaneous Immunoglobulin Without the Use of a Dose-Adjustment Coefficient  Intravenous immunoglobulin (IVIG), a standard therapy for immune deficiency dis-orders, is not appropriate for all patients. As a result, a subcutaneous form (SCIG) has emerged as an alternative. The authors propose a tailored dosing approach for SCIG.   MEETING HIGHLIGHTS American College of Rheumatology and Transcatheter Cardiovascular Therapeutics Rheumatology topics included therapies for rheumatoid arthritis, psoriatic arthritis, and Behçet's syndrome. At the TCT meeting, researchers examined the effects of pharmacological strategies for myocardial infarction, along with platelet function testing as a guide to antiplatelet therapy.   DERMATOLOGY UPDATE Advances in Psoriasis Treatment Experts Comment on Recent Developments Part 1 covers promising biologics that aim to promote safety and efficacy in treating psoriatic lesions. Part 2 addresses the problem of nonadherence to treatment.   Plus our regular columns: Medication Errors, Prescription: Washington, New Drugs/Drug News/New Medical Devices, Pharmaceutical Approval Update, and Drug Forecast. Click here to begin reading the current issue. Click here to subscribe to P&T journal Call for Papers P&T is accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please contact Sonja Sherritze, via phone (267-685-2779) or mobile 267-907-5642) or e-mail (ssherritze@medimedia.com) for more information. We hope you enjoy this issue of P&T. If you have any comments or questions about this digital format, please e-mail us atmail@ptcommunity.com. Sonja Sherritze Editor